Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311905 | 0.85 | SMN1; SMN2 (0.50) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1315261 | 0.82 | HDAC6 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC6 | |
| SCHEMBL1311891 | 0.78 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1312694 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC6 | |
| SCHEMBL27844761 | 0.76 | RIPK1 (0.55) | RIPK1CCNE1CDK2HRH4HRH3 | |
| SCHEMBL1311918 | 0.74 | KDM4E (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1313536 | 0.74 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1311144 | 0.74 | KDM4E (0.62) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1311883 | 0.73 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1312257 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | claimed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | claimed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | claimed |
| EP-2386546-B1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2386546-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RaQualia Pharma Inc (JP) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386546-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RaQualia Pharma Inc (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-RE42840-E1 | Stool flushing device | TOTO, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | RIPK1 2982/4885CHRNB2 261/4885CHRNB4 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.